<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6E1D3BC6-965F-48FE-843D-BFDE496AE8E8"><gtr:id>6E1D3BC6-965F-48FE-843D-BFDE496AE8E8</gtr:id><gtr:name>Summit Plc</gtr:name><gtr:address><gtr:line1>85b Park Drive</gtr:line1><gtr:line2>Milton Park</gtr:line2><gtr:postCode>OX14 4RY</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6E1D3BC6-965F-48FE-843D-BFDE496AE8E8"><gtr:id>6E1D3BC6-965F-48FE-843D-BFDE496AE8E8</gtr:id><gtr:name>Summit Plc</gtr:name><gtr:address><gtr:line1>85b Park Drive</gtr:line1><gtr:line2>Milton Park</gtr:line2><gtr:postCode>OX14 4RY</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E152F8DC-B44A-4592-BCC4-42CF9258AD52"><gtr:id>E152F8DC-B44A-4592-BCC4-42CF9258AD52</gtr:id><gtr:firstName>Kay</gtr:firstName><gtr:surname>Davies</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12021%2F2"><gtr:id>15C84878-BA58-4B93-84B8-C55F4829E813</gtr:id><gtr:title>Molecular analysis of neuromuscular and neurological disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12021/2</gtr:grantReference><gtr:abstractText>Duchenne muscular dystrophy (DMD) is a progressive muscle wasting disorder where patients usually die in their early twenties. Much is now known about the disease pathogenesis and we are using this information to develop novel approaches to treatment. We have collaborated with Summit plc in defining a first in class molecule for increasing the levels of a protein which can compensate for the protein which is missing in patients. This is being taken forward to Phase 2 trials by Summit plc. We have developed an improved assay to identify compounds which could follow on from this into the clinic. We are also developing ways in which to improve the effificiency of exon skipping in DMD which has shown great promise in clinical trials carrried out by other groups. Another aspect of the programme is to study genes expressed in the brain which, when mutated, cause movement and behavoural disorders. By finding out what these genes are, we will be able to identify important genes involved in brain development and function in man which may be relevant to human disease such Parkinsons disease and Amyotrophic lateral sclerosis. One of the mouse mutants is a model for schizophrenia.</gtr:abstractText><gtr:technicalSummary>Our research focusses on the development of a therapy for the devastating progressive wasting disease, Duchenne muscular dystrophy (DMD) and the use of animal models to study to study movement and behavioural disorders in man. It has been known for more than a decade that DMD is caused by the absence of the large muscle protein dystrophin, which results in a fragile muscle membrane. Patients are usually confined to a wheelchair before the age of twelve and die in their early twenties. There is currently no effective treatment. The development of therapy for DMD is challenging because dystrophin is a large structural protein that needs to be delivered to all muscles. We are focussing on the pharmacological up-regulation of the dystrophin-related protein, utrophin as this could be used for all patients independent of the type of mutation. We have collaborated with Summit plc in the high throughput screening for drugs which might increase levels of utrophin in muscle. One candidate drug, SMTC1100 is currently being taken forward to Phase 2 trials by Summit plc. We have developed an improved screening cell line in order to identify further drugs in the future. The second approach to therapy involves exon skipping using U7snRNA AAV vectors. We are exploring ways of improving the efficiency of exon skipping and are investigating strategies for multiexon skipping so that this approach can be used to treat more patients with different mutations. We are analysing several mouse mutants which show movement and behavioural abnormalities. One mutant, named bella, is a recessive mutant which is deleted for the gene Oxr1. We have shown that Oxr1 is involved in protection of the cell in oxidative stress. Interestingly, Oxr1 levels are increased in the spinal cord of Amyotrophic lateral sclerosis (ALS) patients. In an animal model of the disease, Oxr1 levels are increased before the onset of symptoms. We are currently exploring the function of Oxr1 and its role in neurodegenerative diseases. It may be that OXr1 is an early marker of disease which may provide clues to approaches to delaying disease onset. We have also identified a mouse with a mutation in SNAP-25, named blind-drunk, as a potential model for schizophrenia. We have demonstrated that these animals have abnormal circadian rhythms which are very similar to those seen in schizophrenia patients. We are currently investigating the gene expression changes which might underlie these observations. We are also exploring circadian rhythms in other mouse models of neurodegenerative diseases (Alzheimers, Parkinsons) as patients with these disorders also show sleep abnormalities. These studies may identify new pathways which could be targeted for therapies.</gtr:technicalSummary><gtr:fund><gtr:end>2016-04-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-07-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>2165000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Summit Plc</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Utrophin modulation for the therapy of DMD</gtr:description><gtr:id>36BB3B03-2F35-4A7A-A202-9EB07FFB6BF2</gtr:id><gtr:impact>This has resulted in a partnership deal with the University of Oxford to carry our preclinical work to the clinic. Phase 1 trials of one of our drugs has shown it to be safe and well tolerated. Phase 2 trials are in progress.</gtr:impact><gtr:outcomeId>56bb6bc0138852.23374167-1</gtr:outcomeId><gtr:partnerContribution>The partners have given advice on biology and chemistry and also covered the costs of out sourcing for toxicity studies. This collaborative agreement was renewed until 2019 as a result of MRC funding.</gtr:partnerContribution><gtr:piContribution>We have been performing the preclinical testing of drugs for the modulation of utrophin for the therapy of DMD.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Article in Oxford Mail (April 2014)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>EA7A46B9-5F92-409D-8870-7BB2B957976E</gtr:id><gtr:impact>Featured and quoted in an Oxford Mail Article &amp;quot;Running the Town and Gown will help fund new treatment&amp;quot; - 9th April 2014. To encourage public to take part in Town and Gown 10k run to help raise funding for Muscular Dystrophy campaign.

Hopefully increased public participation in the race and fundraising. Also raised local awareness of research on muscular dystrophy being undertaken by the Unit</gtr:impact><gtr:outcomeId>54479db681a7f8.61377776</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.oxfordmail.co.uk/news/11134574.___Running_the_Town_and_Gown_will_help_fund_new_treatment___/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Article for Nature Journal on Antivivisection, April</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1BD6D048-03BD-4BE3-B3C0-1EADC9561354</gtr:id><gtr:impact>This article was written to explain why animal research is crucial in the development of therapy for neuromuscular diseases. It also explained why the restriction of such work would be very detrimental to European scientific research. The article contributed to the debate about proposed EU legislation to limit animal research.</gtr:impact><gtr:outcomeId>56b9ddca554a73.77975834</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>http://www.nature.com/polopoly_fs/1.17479!/menu/main/topColumns/topLeftColumn/pdf/521007a.pdf</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sky News Interview March 2014</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>44BDEB6E-4921-44BD-908D-7A0E7A93113F</gtr:id><gtr:impact>Sky News Interview on utrophin modulation and the collaboration between Summit plc and charities. - 13th March 2014

Greater national public awareness of research on muscular dystrophy being undertaken within the Unit</gtr:impact><gtr:outcomeId>544799a7ba7379.96152752</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Muscular Dystrophy Association Scientific Conference</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>29224FDD-4C5E-49BE-B433-13E3B408C6E8</gtr:id><gtr:impact>Talk at the Muscular Dystrophy Association Scientific Conference, 23rd April. on utrophin modulation</gtr:impact><gtr:outcomeId>56c3301cade589.44817552</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public talk on sleep at Oxford May Music Festival, 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>3F965378-FFA4-4E1D-9B2B-F477C811FE4B</gtr:id><gtr:impact>Dr Peter Oliver (Davies Group) gave a public talk on sleep and circadian rhythm research at the Oxford May Music Festival at the Holywell Music Rooms, 1 May 2013


Greater public awareness of research work into circadian disruption being undertaken by the Unit and MRC</gtr:impact><gtr:outcomeId>QMCEYfLVCdN</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Video for DMD For F1000</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>19824A92-D6CE-4A32-8508-43AE4F10FEB8</gtr:id><gtr:impact>The video was to increase awareness of muscular dystrophy and explain how genetic approaches to therapy are working.</gtr:impact><gtr:outcomeId>56b9dce811f994.20823110</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>100 Leading Ladies - Portrait and interview (2014)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F5A76C4F-DF73-4CEA-888F-7F4386EE0FDF</gtr:id><gtr:impact>Professor Dame Kay Davies included in Nancy Honey's 2014 book and exhibition of &amp;quot;100 Leading Ladies - portraits and interviews with influential senior women in Britain&amp;quot;

Raising public awareness of women in science and research on muscular dystrophy being undertaken by the Unit and MRC</gtr:impact><gtr:outcomeId>5447a8200d8ce5.74646537</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.thesorority.org/100leadingladies.asp</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Short Report - The Royal Society - Recent developments in personalised medicine</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CFF4A446-3C3A-4B09-BE61-50B949520AB2</gtr:id><gtr:impact>The purpose of this report was to convey the importance of genomics in clinical medicine. It provided an update on progress made since a major report has been produced on this subject several year's ago.</gtr:impact><gtr:outcomeId>56b9de73c08181.77420870</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description> '50 Movers and Shakers in Biobusiness, 2014' list</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F447CD06-D7A7-459D-A1A1-06AF791DF5E7</gtr:id><gtr:impact>Professor Dame Kay Davies has been included in a special report on '50 Movers and Shakers in Biobusiness, 2014' which identifies 50 women in biobusiness in the UK who are challenging norms and bringing better health to people around the world.

Greater awareness of women in science and research being undertaken by the Unit and MRC</gtr:impact><gtr:outcomeId>5447afe6acc1b8.66797293</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.onenucleus.com/news?id=4340</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Telephone interview Canadian Medical Association Journal (2014)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CCF8A0B3-5D94-4828-8D8F-E6E2B09E319D</gtr:id><gtr:impact>Telephone interview for Canadian Medical Association Journal for UCB and development of new disease prevention strategies

Raised awareness of the impact of genetics/genomics in clinical medicine</gtr:impact><gtr:outcomeId>544524725beaa1.68430997</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Panel member - Action Duchenne conference 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>309E5964-D2F8-4BBD-B5E0-3C888EF4070A</gtr:id><gtr:impact>Professor Dame Kay Davies was a panel member for &amp;quot;Ask the Duchenne Experts! Panel interactive session&amp;quot; - 12th Action Duchenne International Annual Conference, Institute of Education, London. 7th and 8th November 2014



Greater international awareness of muscular dystrophy research and work of both the FGU and MRC</gtr:impact><gtr:outcomeId>5447ba9d59b8a9.97272020</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.actionduchenne.org/conference/registration/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Award presenter at The Comments Award (2014)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>42064F15-1167-4E81-925A-ECE12315127C</gtr:id><gtr:impact>Presenting the Science Commentator award for Editorial Intelligence at The Comments Awards, RIBA, London. 25th November. These are national awards appearing in the national press.

Greater awareness of the impact of science on society through the publication of short articles.</gtr:impact><gtr:outcomeId>544a3e169cf918.05649811</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://commentawards.com/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview - People Behind the Science August 2014</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A923B98E-62F5-460E-B66E-926320D7D9F9</gtr:id><gtr:impact>Interview/podcast for People Behind the Science website. &amp;quot;;136: Dr. Kay Davies: Not Wasting Any Time in Search of Genetic Treatments for Muscular Dystrophy&amp;quot;

Greater awareness of women in science and research on muscular dystrophy being undertaken by the Unit and MRC</gtr:impact><gtr:outcomeId>5447b65edd1a24.06967304</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.peoplebehindthescience.com/?s=kay+davies</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk - Women in Science (University of Oxford Athena Swan group)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C5FC6EB6-3D95-4675-8F9F-FDC31F84CFC7</gtr:id><gtr:impact>Professor Dame Kay Davies gave a talk entitled &amp;quot;Life as a woman in science to the Women in Science in South Parks Road (Athena Swan) - A Seminar Series for Everyone Interested in Equality and Diversity. This resulted in more discussion on how women can succeed in science.



Greater awareness amongst women scientists of opportunities open to them</gtr:impact><gtr:outcomeId>5447b7ce135e91.80433537</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research Blog - Motor Neuron Disease (MND) - Oxidation Resistance 1 - Tackling oxidative stress - June</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7BF9D3FB-DD94-4A59-989A-11A763899537</gtr:id><gtr:impact>This was a summary of the impact of our research observation for the development of treatment for ALS and explained the role of oxidative stress in the disease.</gtr:impact><gtr:outcomeId>56b9de40cc5303.92171754</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview for Increasing Women's representation on company boards reseaerch for Oxford Brookes University</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CECFE9DC-ACEB-4296-AE71-37C613BFA16F</gtr:id><gtr:impact>An informal presentation on the role of women on boards</gtr:impact><gtr:outcomeId>58c12de5e33d43.28163647</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lay Work for Harrison Fund Muscular Dystrophy</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CA7DA9A8-9B0E-4A9B-8A8A-89FB1F618362</gtr:id><gtr:impact>The interview was to explain my work to an educated lay audience to raise awareness of muscular dystrophy and how genetics can play a role in the development of therapies.</gtr:impact><gtr:outcomeId>56b9dd3852b3a9.78341286</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview for Research Fortnight, July 2013</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7F045FF5-17CA-4B84-BCF4-6B06880AC5CB</gtr:id><gtr:impact>Interview for Research Fortnight, 29 July 2013

Greater international awareness of the work of both the FGU and MRC</gtr:impact><gtr:outcomeId>jcBcUwVowef</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.researchresearch.com/index.php?option=com_content&amp;view=article&amp;id=16&amp;Itemid=16</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Joint Conference of the AfSHG and the H3Africa Consortium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3755291B-941F-4E3C-AD83-81D418B18870</gtr:id><gtr:impact>Keynote Address at the Joint Conference of the AfSHG and the H3 Africa Consortium.</gtr:impact><gtr:outcomeId>56c33085307343.18108070</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2013,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Speech, Fundraiser for JJ and DCT - The Duchenne Dinner, London - April</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5F7F949B-310D-4A6F-AE1A-AD4F15B41D0A</gtr:id><gtr:impact>This was a speech at a fundraising dinner to raise monies for research and development of treatment for Duchenne muscular dystrophy. It also raised awareness of the disease. The presentation was made into a video which is used by other muscular dystrophy charities and parent groups.</gtr:impact><gtr:outcomeId>56b9ddfdb4da68.51055327</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dorothy Hodgkin Lecture - &quot;Therapy for Duchenne muscular dystrophy: time for optimism&quot;</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C89BA649-FEC9-440C-88FF-06388C150E57</gtr:id><gtr:impact>Natural History Museum Talk on therapy of muscular dystrophy. Lay talk</gtr:impact><gtr:outcomeId>56c32e524f3b76.34539926</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Chairman, Women in Science and Business Event, The Wellcome Trust, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>22C0A55C-89CC-4167-A715-B1A035C4B280</gtr:id><gtr:impact>This day was set up to expose young female scientists to the opportunities for leadership for women in business and science. Speakers included senior women from banking and retail as well as eminent female scientists. There were useful parallels between being at the top in science and being at the top in business. Anne Richards from Aberdeen Asset Management was the co-chair. The purpose was to encourage more female scientists to aim for the top.</gtr:impact><gtr:outcomeId>56b9dd777344c9.78219719</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>100 leading practising scientists 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E4DCF837-EA84-461A-80DD-3DE0C4C27853</gtr:id><gtr:impact>Professor Dame Kay Davies was included within the list of the Science Council's &amp;quot;100 leading practising scientists&amp;quot; in the UK in 2014

Greater awareness of women in science and research on muscular dystrophy being undertaken by the Unit and MRC</gtr:impact><gtr:outcomeId>5447adcb8e3705.21940430</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.sciencecouncil.org/content/100-leading-uk-practising-scientists</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Video for WISE</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8964CF48-7D0F-4093-BEA8-6B08D7E1B384</gtr:id><gtr:impact>This video explained my career as a women in science and the hurdles that need to be overcome to get to the top and be successful.</gtr:impact><gtr:outcomeId>56b9dcb94b4045.02905141</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Portraits Display Event - Hertford College, Oxford (2014)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DD8060E7-136D-4034-ABFD-6B39278A4A16</gtr:id><gtr:impact>Press releases and portrait exhibition - Professor Dame Kay Davies' portrait was amongst those hung in Hertford College great hall to celebrate/raise the profile of female fellows and graduates

Raised awareness of women in science</gtr:impact><gtr:outcomeId>5447b9ac121f26.19920355</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.theguardian.com/education/2014/sep/21/oxford-hertford-college-portraits-women-co-ed</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>95826</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Motor Neurone Disease Association Studentship (MW)</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:fundingRef>Davies/Oct13/6203</gtr:fundingRef><gtr:id>2750AC40-5D26-4CDC-8E30-C6CE45A70BEE</gtr:id><gtr:outcomeId>54451d560d1190.05195249</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>95826</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Investigating novel protective mechanisms in motor neurons</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:id>F16BFAA5-1337-4F8B-8B17-D14E2C0626B3</gtr:id><gtr:outcomeId>56bb180cc16127.13830503</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2018279</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The role of utrophin in DMD and its therapeutic potential</gtr:description><gtr:end>2021-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>8B14BF1B-9208-4606-9F2D-C8D8356122A3</gtr:id><gtr:outcomeId>56bb19d4eb6095.29318855</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Development of utrophin modulators for DMD</gtr:description><gtr:end>2019-11-02</gtr:end><gtr:fundingOrg>Summit Plc</gtr:fundingOrg><gtr:id>90E864CA-1FD9-46E0-8F4A-F42CB67DBB74</gtr:id><gtr:outcomeId>56bb197ba3b664.89798873</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>128064</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Development of small molecule upregulators of utrophin for the treatment of Duchenne muscular dystrophy</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Muscular Dystrophy UK</gtr:fundingOrg><gtr:id>F494A8AD-8EE7-4A1B-890F-D6B49C7E5FC2</gtr:id><gtr:outcomeId>56bb18a5ec1651.51706136</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>An alliance was made between Summit plc and ISIS for the development of a therapy for Duchenne muscular Dystrophy using utrophin modulation.</gtr:description><gtr:grantRef>MC_UU_12021/2</gtr:grantRef><gtr:id>E0708737-4B55-477C-8218-600B7146E036</gtr:id><gtr:impact>Funding of research in Professor Davies's group from Summit plc</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>544a575f0af5c1.86109981</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>Alliance between Summit plc and ISIS Innovation at Oxford</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Parliamentary briefing - launch of All Party Parliamentary Group for Muscular Dystrophy inquiry report, 30 April 2014</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>178C5E37-2727-4A89-9AC8-C9F5AF3E41AC</gtr:id><gtr:outcomeId>5447bcee129dd4.94183736</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Roundtable discussion on a new &amp;quot;longitude&amp;quot; prize for 2014 at 10 Downing Street, London. 29th April</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5F63E34F-C0B8-4536-9570-420B7B3BF6E7</gtr:id><gtr:impact>Led to the choice of antibiotics as the subject for the prize.</gtr:impact><gtr:outcomeId>L18XRQWjW4U</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Mouse muscle sections from wt and sync-/-</gtr:description><gtr:id>DED6CE84-DC3C-497C-BB62-FE61D0C5067A</gtr:id><gtr:impact>MTA currently under negotiation with University of Brussels</gtr:impact><gtr:outcomeId>rJRr8jhgtnM</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Mouse Muscle sections Wt and Sync-/-</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Antibodies to syncoilin that work well in tissue and blots</gtr:description><gtr:id>83E27077-E18F-4472-A283-F230FE135909</gtr:id><gtr:impact>MTA currently under negotiation with University of Brussels</gtr:impact><gtr:outcomeId>ckoEJARzKU5</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Syncoilin antibodies - Nterm,Sync 1, Sync2</gtr:title><gtr:type>Antibody</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>2FFBC716-986B-455B-86BF-96C05A69FB67</gtr:id><gtr:title>G.P.89</gtr:title><gtr:parentPublicationTitle>Neuromuscular Disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e5173ec375ae025674e9df6b96f3ee1"><gtr:id>3e5173ec375ae025674e9df6b96f3ee1</gtr:id><gtr:otherNames>Fairclough R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>56b0b040387265.89282152</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D19780AB-E9A8-4128-8A50-6218FFAF4E51</gtr:id><gtr:title>Cardiac a-actin over-expression therapy in dominant ACTA1 disease.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ade73ea2e70d7526d9f8069b3315b03"><gtr:id>0ade73ea2e70d7526d9f8069b3315b03</gtr:id><gtr:otherNames>Ravenscroft G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>54463679e2df24.03467128</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B99310E0-87DD-4B5D-BAD3-3B76DCF5497B</gtr:id><gtr:title>Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d8f3bb060500a5be403ba0bef3f0811"><gtr:id>9d8f3bb060500a5be403ba0bef3f0811</gtr:id><gtr:otherNames>Ricotti V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58aae8e070f858.19681347</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C02CB45-52A7-41B2-A335-A8F77727D836</gtr:id><gtr:title>2015 William Allan Award.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a3c138a9c2bf9a342e30789d695e3f7"><gtr:id>8a3c138a9c2bf9a342e30789d695e3f7</gtr:id><gtr:otherNames>Davies KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>58aae93fe224e6.39172958</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC7DA60F-1CF3-471C-A58D-7C813475FFD1</gtr:id><gtr:title>Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c745e5f96e2db4ca9a165bd1a95a4858"><gtr:id>c745e5f96e2db4ca9a165bd1a95a4858</gtr:id><gtr:otherNames>Tremblay JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>pm_13072_22_23369965</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE8544F3-CD0F-4EBE-814C-6A29F2E703A9</gtr:id><gtr:title>Laf4/Aff3, a gene involved in intellectual disability, is required for cellular migration in the mouse cerebral cortex.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcd63590b7ff2c298fa07a3b7185366c"><gtr:id>dcd63590b7ff2c298fa07a3b7185366c</gtr:id><gtr:otherNames>Moore JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>543fd3026532f2.97036407</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83BB973D-3DA4-4B87-B503-C1A3C3244144</gtr:id><gtr:title>Neuron-specific antioxidant OXR1 extends survival of a mouse model of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb5ab0d10aa8777904aad54c57ac0144"><gtr:id>eb5ab0d10aa8777904aad54c57ac0144</gtr:id><gtr:otherNames>Liu KX</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56b0b06bbe2539.54966825</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FE1E3FF-AE80-422E-914E-C19348D09D5B</gtr:id><gtr:title>Second-generation compound for the modulation of utrophin in the therapy of DMD.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52b4babf7b22c1bb650c3b41a2537d52"><gtr:id>52b4babf7b22c1bb650c3b41a2537d52</gtr:id><gtr:otherNames>Guiraud S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56b0b06d1cf7f7.12424481</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C4FDF98-6113-44FD-99A4-BF633BE58DF3</gtr:id><gtr:title>Chondrolectin affects cell survival and neuronal outgrowth in in vitro and in vivo models of spinal muscular atrophy.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2429b632bedd79bf4ea4a09b0209d4fb"><gtr:id>2429b632bedd79bf4ea4a09b0209d4fb</gtr:id><gtr:otherNames>Sleigh JN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>543fd3018becd6.99615174</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23DCC0B8-8F6D-4BEF-BA71-74D6BEB1269A</gtr:id><gtr:title>Advances in genetic therapeutic strategies for Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Experimental physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52b4babf7b22c1bb650c3b41a2537d52"><gtr:id>52b4babf7b22c1bb650c3b41a2537d52</gtr:id><gtr:otherNames>Guiraud S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0958-0670</gtr:issn><gtr:outcomeId>56c331dc4aacf9.26141896</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9272E736-0E28-4A90-B5B5-FF7970375B68</gtr:id><gtr:title>Temporal transcriptomics suggest that twin-peaking genes reset the clock.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/356d4b3db081ca136cdcf5e3fbe9b488"><gtr:id>356d4b3db081ca136cdcf5e3fbe9b488</gtr:id><gtr:otherNames>Pembroke WG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>58aae83f589385.06423077</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5FC83D2-BD20-40A7-9B43-030748DF7966</gtr:id><gtr:title>The mutant Moonwalker TRPC3 channel links calcium signaling to lipid metabolism in the developing cerebellum.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/073e3460cd854b29b3dcdb2b6954cf8f"><gtr:id>073e3460cd854b29b3dcdb2b6954cf8f</gtr:id><gtr:otherNames>Dulneva A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56b0b06ce066d6.68163357</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA856208-2B28-42EF-AE24-F28883F942F4</gtr:id><gtr:title>The antioxidant protein Oxr1 influences aspects of mitochondrial morphology.</gtr:title><gtr:parentPublicationTitle>Free radical biology &amp; medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1ae91a136cc1808e002adb45e242f69"><gtr:id>e1ae91a136cc1808e002adb45e242f69</gtr:id><gtr:otherNames>Wu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0891-5849</gtr:issn><gtr:outcomeId>58aae8a47c8b25.49430122</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D6A32F6-FA47-40CC-AA18-E6BE430AE867</gtr:id><gtr:title>Acne reaudit with emphasis on primary care referral patterns</gtr:title><gtr:parentPublicationTitle>BRITISH JOURNAL OF DERMATOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4fc970228993605e1d45dea0e99a68e4"><gtr:id>4fc970228993605e1d45dea0e99a68e4</gtr:id><gtr:otherNames>Davies K. E.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>56b0b06c3eb649.52412811</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAD5A95A-EEDE-450D-940C-63A82BBD440A</gtr:id><gtr:title>Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to healthy male adult volunteers.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac4009a10aa49611407f0e5dbbe15cb4"><gtr:id>ac4009a10aa49611407f0e5dbbe15cb4</gtr:id><gtr:otherNames>Tinsley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0091-2700</gtr:issn><gtr:outcomeId>56b0b06cb90089.27228225</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A27C5429-BAA9-4AF3-AFB5-7698ECE98790</gtr:id><gtr:title>The Pathogenesis and Therapy of Muscular Dystrophies.</gtr:title><gtr:parentPublicationTitle>Annual review of genomics and human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52b4babf7b22c1bb650c3b41a2537d52"><gtr:id>52b4babf7b22c1bb650c3b41a2537d52</gtr:id><gtr:otherNames>Guiraud S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1527-8204</gtr:issn><gtr:outcomeId>56b0b06c7cc108.13768675</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EC3B651-DA0B-4D2C-9985-52661F041700</gtr:id><gtr:title>Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/434db71ab5da35406218fe1e97a96474"><gtr:id>434db71ab5da35406218fe1e97a96474</gtr:id><gtr:otherNames>Janghra N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58aae918a57473.84284833</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>714D3B4F-E8BB-477A-9484-C2DEF21B2335</gtr:id><gtr:title>Syncoilin is an intermediate filament protein in activated hepatic stellate cells.</gtr:title><gtr:parentPublicationTitle>Histochemistry and cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd4463882d8d20eb09f18ef887e7d370"><gtr:id>bd4463882d8d20eb09f18ef887e7d370</gtr:id><gtr:otherNames>Van Rossen E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0948-6143</gtr:issn><gtr:outcomeId>543fd3015aad70.04038300</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4165B57-DCE6-494F-B0FC-D036E1549E0C</gtr:id><gtr:title>Circadian profiling in two mouse models of lysosomal storage disorders; Niemann Pick type-C and Sandhoff disease.</gtr:title><gtr:parentPublicationTitle>Behavioural brain research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f624f0460d50672dc99818a4b81066b"><gtr:id>9f624f0460d50672dc99818a4b81066b</gtr:id><gtr:otherNames>Richardson K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0166-4328</gtr:issn><gtr:outcomeId>56b0b08bd47208.14640310</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D0C7EAA-FA64-4DD2-BB68-17C8C77C29AA</gtr:id><gtr:title>The Evolutionarily Conserved Tre2/Bub2/Cdc16 (TBC), Lysin Motif (LysM), Domain Catalytic (TLDc) Domain Is Neuroprotective against Oxidative Stress.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f08010d8d2394208e5c4cc94ef34a73"><gtr:id>7f08010d8d2394208e5c4cc94ef34a73</gtr:id><gtr:otherNames>Finelli MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>58aae806847397.58986108</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CAC6775-1488-488F-AF3D-8D7226AD2FE1</gtr:id><gtr:title>Oxr1 improves pathogenic cellular features of ALS-associated FUS and TDP-43 mutations.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f08010d8d2394208e5c4cc94ef34a73"><gtr:id>7f08010d8d2394208e5c4cc94ef34a73</gtr:id><gtr:otherNames>Finelli MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56b0b06d444c11.31725246</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE8BEB0D-F69E-43B7-A5B1-6BA77045E016</gtr:id><gtr:title>Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P a-synuclein BAC transgenic mouse.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b87408ab4631e28cdf76393ba4d8012b"><gtr:id>b87408ab4631e28cdf76393ba4d8012b</gtr:id><gtr:otherNames>Taylor TN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>543fd302018558.48934236</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E252AEA-0E38-4BF2-8A2E-6C0797A387E6</gtr:id><gtr:title>A novel mouse model of a patient mucolipidosis II mutation recapitulates disease pathology.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80f4095fa6e5e88b4c63ebd2216a5685"><gtr:id>80f4095fa6e5e88b4c63ebd2216a5685</gtr:id><gtr:otherNames>Paton L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>543fd30232e6d4.27677383</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71454D78-1E60-4C8C-A0A3-89BBA5BA7E30</gtr:id><gtr:title>Overexpression of survival motor neuron improves neuromuscular function and motor neuron survival in mutant SOD1 mice.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cb91d9b5f1db29dabc665314e353a66"><gtr:id>6cb91d9b5f1db29dabc665314e353a66</gtr:id><gtr:otherNames>Turner BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>543fd301c07c92.45350832</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B775C74-2511-45B2-BA97-F1B27E089B85</gtr:id><gtr:title>Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a6cbf20c5cc231809c413715c6e77d8"><gtr:id>9a6cbf20c5cc231809c413715c6e77d8</gtr:id><gtr:otherNames>Fairclough RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-0056</gtr:issn><gtr:outcomeId>pm_13072_22_23609411</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12021/2</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>67</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>